NasdaqGM:VRAY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has ViewRay's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VRAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: VRAY's weekly volatility has decreased from 13% to 8% over the past year.


Market Performance


7 Day Return

-5.9%

VRAY

2.2%

US Medical Equipment

1.5%

US Market


1 Year Return

-8.0%

VRAY

20.0%

US Medical Equipment

22.3%

US Market

Return vs Industry: VRAY underperformed the US Medical Equipment industry which returned 19% over the past year.

Return vs Market: VRAY underperformed the US Market which returned 22.1% over the past year.


Shareholder returns

VRAYIndustryMarket
7 Day-5.9%2.2%1.5%
30 Day21.3%3.4%8.8%
90 Day33.1%8.8%10.8%
1 Year-8.0%-8.0%21.0%20.0%25.1%22.3%
3 Year-57.8%-57.8%76.0%71.5%49.5%39.6%
5 Year-26.0%-26.0%147.7%128.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is ViewRay's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ViewRay undervalued compared to its fair value and its price relative to the market?

3.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VRAY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VRAY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VRAY is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: VRAY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VRAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VRAY is good value based on its PB Ratio (3.6x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is ViewRay forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

11.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VRAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VRAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VRAY's revenue (26.6% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: VRAY's revenue (26.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VRAY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ViewRay performed over the past 5 years?

-21.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VRAY is currently unprofitable.

Growing Profit Margin: VRAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VRAY is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare VRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VRAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).


Return on Equity

High ROE: VRAY has a negative Return on Equity (-77.48%), as it is currently unprofitable.


Next Steps

Financial Health

How is ViewRay's financial position?


Financial Position Analysis

Short Term Liabilities: VRAY's short term assets ($254.5M) exceed its short term liabilities ($81.3M).

Long Term Liabilities: VRAY's short term assets ($254.5M) exceed its long term liabilities ($57.8M).


Debt to Equity History and Analysis

Debt Level: VRAY's debt to equity ratio (36.9%) is considered satisfactory.

Reducing Debt: VRAY's debt to equity ratio has reduced from 443.5% to 36.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VRAY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VRAY has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 22.1% each year.


Next Steps

Dividend

What is ViewRay current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VRAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VRAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VRAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Scott Drake (52 yo)

2.42yrs

Tenure

US$5,553,232

Compensation

Mr. Scott William Drake has been the President, Chief Executive Officer and Director of ViewRay, Inc., since July 24, 2018. Mr. Drake is Chairman and Director of AtriCure Inc. since May 22, 2018 and Septem...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD5.55M) is above average for companies of similar size in the US market ($USD1.79M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Drake
President2.42yrsUS$5.55m0.23%
$ 1.3m
Shahriar Matin
Chief Operating Officer2.42yrsUS$3.98m0.29%
$ 1.6m
James Dempsey
Chief Scientific Officer16.75yrsUS$1.70m0.15%
$ 842.6k
Zachary Stassen
Chief Financial Officer0.58yrno data0.23%
$ 1.3m
Michaella Gallina
VP. Chief of Staff and Head of Investor Relations & Communicationsno datano datano data
Robert McCormack
Senior VP2.33yrsno datano data
Michael Saracen
Vice President of Marketingno datano datano data
Robert Fuchs
Chief Human Resources Officer2.17yrsno datano data
Martin Fuss
Chief Medical Officerno datano datano data

2.4yrs

Average Tenure

50.5yo

Average Age

Experienced Management: VRAY's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Drake
President2.42yrsUS$5.55m0.23%
$ 1.3m
Caley Castelein
Independent Director12.92yrsUS$177.00k0.46%
$ 2.5m
D. Grossman
Independent Director2.42yrsUS$170.00k0.063%
$ 344.3k
R. Huennekens
Independent Director2.83yrsUS$175.00k0.067%
$ 368.8k
Brian Roberts
Independent Director5yrsUS$190.00k0%
$ 0
Carlos Perez
Member of Scientific Advisory Boardno datano datano data
Daniel Moore
Independent Chairman2.83yrsUS$205.00k0.021%
$ 116.1k
John Bayouth
Member of Scientific Advisory Board4.58yrsno datano data
Jeffrey Bradley
Member of Scientific Advisory Board4.58yrsno datano data
Michael Steinberg
Member of Scientific Advisory Board4.58yrsno datano data
Vincenzo Valentini
Member of Scientific Advisory Board4.58yrsno datano data
Hong-Gyun Wu
Member of Scientific Advisory Board4.58yrsno datano data

4.6yrs

Average Tenure

54yo

Average Age

Experienced Board: VRAY's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VRAY insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.


Top Shareholders

Company Information

ViewRay, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ViewRay, Inc.
  • Ticker: VRAY
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$549.449m
  • Shares outstanding: 148.50m
  • Website: https://www.viewray.com

Number of Employees


Location

  • ViewRay, Inc.
  • 2 Thermo Fisher Way
  • Oakwood
  • Ohio
  • 44146
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VRAYNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2015
6L9DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MR...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/05 00:26
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.